Biogen (BIIB) Competitors $139.54 +2.46 (+1.79%) As of 02:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BIIB vs. REGN, ALNY, UTHR, INCY, BMRN, NBIX, EXEL, EXAS, RGEN, and HALOShould you be buying Biogen stock or one of its competitors? The main competitors of Biogen include Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry. Biogen vs. Regeneron Pharmaceuticals Alnylam Pharmaceuticals United Therapeutics Incyte BioMarin Pharmaceutical Neurocrine Biosciences Exelixis Exact Sciences Repligen Halozyme Therapeutics Regeneron Pharmaceuticals (NASDAQ:REGN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, community ranking, analyst recommendations, profitability and risk. Is REGN or BIIB more profitable? Regeneron Pharmaceuticals has a net margin of 31.07% compared to Biogen's net margin of 16.87%. Regeneron Pharmaceuticals' return on equity of 16.32% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Regeneron Pharmaceuticals31.07% 16.32% 12.76% Biogen 16.87%14.98%8.76% Does the media favor REGN or BIIB? In the previous week, Biogen had 3 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 55 mentions for Biogen and 52 mentions for Regeneron Pharmaceuticals. Biogen's average media sentiment score of 0.57 beat Regeneron Pharmaceuticals' score of 0.46 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 27 Very Positive mention(s) 1 Positive mention(s) 23 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biogen 19 Very Positive mention(s) 6 Positive mention(s) 10 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Positive Do analysts prefer REGN or BIIB? Regeneron Pharmaceuticals presently has a consensus target price of $973.13, indicating a potential upside of 39.63%. Biogen has a consensus target price of $211.85, indicating a potential upside of 52.33%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Regeneron Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regeneron Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 16 Buy rating(s) 2 Strong Buy rating(s) 2.76Biogen 0 Sell rating(s) 17 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.43 Does the MarketBeat Community believe in REGN or BIIB? Biogen received 268 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 71.55% of users gave Biogen an outperform vote while only 66.93% of users gave Regeneron Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRegeneron PharmaceuticalsOutperform Votes154866.93% Underperform Votes76533.07% BiogenOutperform Votes181671.55% Underperform Votes72228.45% Which has more volatility & risk, REGN or BIIB? Regeneron Pharmaceuticals has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500. Comparatively, Biogen has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500. Do institutionals & insiders believe in REGN or BIIB? 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 7.5% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has higher earnings & valuation, REGN or BIIB? Regeneron Pharmaceuticals has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegeneron Pharmaceuticals$14.20B5.36$4.41B$38.2818.21Biogen$9.68B2.10$1.63B$11.1912.43 SummaryRegeneron Pharmaceuticals beats Biogen on 13 of the 19 factors compared between the two stocks. Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIIB vs. The Competition Export to ExcelMetricBiogenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.36B$3.13B$5.81B$9.13BDividend YieldN/A1.57%4.78%3.85%P/E Ratio12.4329.9025.9319.18Price / Sales2.10373.33463.3381.20Price / Cash5.91183.5344.0437.47Price / Book1.223.647.714.77Net Income$1.63B-$71.72M$3.18B$245.80M7 Day Performance1.27%0.03%-0.52%-0.80%1 Month Performance-1.35%2.67%1.71%-0.44%1 Year Performance-37.10%-9.50%18.52%16.44% Biogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIIBBiogen4.7769 of 5 stars$139.55+1.8%$211.85+51.8%-37.5%$20.43B$9.68B12.477,605Analyst ForecastREGNRegeneron Pharmaceuticals4.6472 of 5 stars$673.60-0.1%$973.13+44.5%-26.5%$74.02B$14.20B17.6013,450Dividend AnnouncementALNYAlnylam Pharmaceuticals4.5539 of 5 stars$256.45-3.2%$299.43+16.8%+68.7%$33.08B$1.83B-97.882,100Analyst ForecastInsider TradeUTHRUnited Therapeutics4.4129 of 5 stars$370.58+0.0%$382.08+3.1%+71.5%$16.55B$2.33B16.271,168Insider TradeINCYIncyte4.5814 of 5 stars$70.42+0.6%$75.59+7.3%+21.4%$13.57B$3.70B503.042,524BMRNBioMarin Pharmaceutical4.9364 of 5 stars$64.85+0.7%$94.20+45.3%-22.5%$12.36B$2.42B38.833,401Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageNBIXNeurocrine Biosciences4.9783 of 5 stars$115.02-1.6%$166.90+45.1%-12.5%$11.65B$2.36B34.961,400Analyst DowngradeAnalyst RevisionGap UpEXELExelixis4.6803 of 5 stars$35.00+1.5%$37.24+6.4%+70.1%$10.00B$1.83B22.441,310Analyst UpgradeInsider TradeGap UpEXASExact Sciences4.671 of 5 stars$49.31-2.5%$72.76+47.6%-21.1%$9.13B$2.50B-42.146,600Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageRGENRepligen4.3262 of 5 stars$146.92+0.5%$182.91+24.5%-18.6%$8.23B$638.76M-397.071,783Earnings ReportAnalyst ForecastNews CoverageHALOHalozyme Therapeutics4.5001 of 5 stars$58.29-0.5%$60.89+4.5%+59.6%$7.42B$829.25M19.30390Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors United Therapeutics Competitors Incyte Competitors BioMarin Pharmaceutical Competitors Neurocrine Biosciences Competitors Exelixis Competitors Exact Sciences Competitors Repligen Competitors Halozyme Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BIIB) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIIB Stock Alerts